Nevertheless, the mutation (10/440, 2.27%) and amplification (6/440, 1.36%) of YARS were relatively rare in gastric cancer, hence our study majorly focuses on the malignant function of YARS’s expressional changes. This evidence concerns the gene YARS1 and gastric cancer.